Skip to main content
ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
8.67
-0.29 (-3.24%)
At close: Mar 6, 2026, 4:00 PM EST
8.64
-0.03 (-0.35%)
After-hours: Mar 6, 2026, 7:59 PM EST

ImmunityBio Revenue

In the year 2025, ImmunityBio had annual revenue of $113.29M with 668.31% growth. ImmunityBio had revenue of $38.29M in the quarter ending December 31, 2025, with 406.95% growth.

Revenue (ttm)
$113.29M
Revenue Growth
+668.31%
P/S Ratio
78.68
Revenue / Employee
$163,948
Employees
691
Market Cap
8.91B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2025113.29M98.54M668.31%
Dec 31, 202414.75M14.12M2,270.58%
Dec 31, 2023622.00K382.00K159.17%
Dec 31, 2022240.00K-694.00K-74.30%
Dec 31, 2021934.00K329.00K54.38%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Exelixis 2.32B
Halozyme Therapeutics 1.40B
Bio-Techne 1.22B
Arrowhead Pharmaceuticals 1.09B
Madrigal Pharmaceuticals 958.40M
Axsome Therapeutics 638.50M
Cytokinetics 88.04M
Praxis Precision Medicines 7.46M
Revenue Rankings

IBRX News

More News